News Center

位置：

Honors Announcement

Group News

Media Reports

Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group: Delivering a “Combination Punch” of Innovation to Seize the Initiative in Development

Category:

Media Reports

发布时间：2022-04-20

【概要描述】 Its flagship product, caffeine, has seen robust growth across both production and sales; seven new specialty API products, including pentoxifylline and ornidazole, are poised for approval and market launch; and first-quarter core business revenue posted triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has delivered a powerful “combination punch,” delivering a strong start to its innovative development.

Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group: Delivering a “Combination Punch” of Innovation to Seize the Initiative in Development

Its flagship product, caffeine, has seen robust growth across production and sales, while seven new specialty API products—including pentoxifylline and ornidazole—are poised for approval and market launch. In the first quarter, the company’s core business revenue posted triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has delivered a powerful “combination punch,” securing a strong start to its innovative development.

“Seizing opportunities and extending and strengthening our industrial chain has created new prospects for our development. The strong performance in the first quarter was, to a significant extent, driven by this acquisition. In early March, we acquired 100% of the equity in Cangzhou Lingang Youyi Chemical Co., Ltd., a leading domestic producer of methylamine-based products, which has given Guangxiang Pharmaceutical a powerful boost and added substantial competitive leverage in the market.” Speaking about this successful capital transaction, Cui Yongbin, Chairman of Guangxiang Pharmaceutical, said with enthusiasm that caffeine is a highly sought-after commodity in the international market, and maintaining tight control over production costs is the key to sustained market success. Among the various cost components in caffeine production, monomethylamine accounts for a considerable share. By acquiring Youyi Chemical, which is located in the same industrial park, Guangxiang Pharmaceutical has not only achieved notable reductions in caffeine production costs but has also effectively addressed the coordination between upstream and downstream links in the supply chain and improved supply management. This has made the entire industrial chain more integrated and efficient, enhancing the company’s influence in both domestic and international markets.

“Capital mergers and acquisitions have been commendable, but technological advancement has been equally indispensable; together, these efforts have solidified our core competitiveness,” said Cui Yongbin. Guangxiang Pharmaceutical serves as the strategic hub for Shisiyao Group’s initiative to establish an “API-plus-formulation” business model, accelerate industrial transformation, and strengthen and extend the industry chain. The goal is to develop it into a new high ground for innovative, high-quality API development in China and to make it a core pillar of the industry’s growth. In recent years, leveraging research-and-development mechanisms such as the “challenge-based recruitment” system, Guangxiang Pharmaceutical has spearheaded collaborative efforts to tackle key core technologies in API production. Through flexible talent-acquisition strategies and with the support and guidance of research teams from Tsinghua University and Tianjin University, numerous common and critical technical bottlenecks that had long constrained the yield and quality of its flagship product—caffeine—have been resolved, leading to a doubling of output and full-capacity operation. In the first quarter, the plant’s caffeine exports accounted for more than 30% of China’s total caffeine exports. Meanwhile, the efficiency of new-product R&D has also been accelerating: seven new products—including pentoxifylline, ornidazole, levornidazole, and pitavastatin calcium—are expected to receive approval and enter commercial production in the near future, further highlighting the plant’s role as a model and driver of “specialized, refined, distinctive, and innovative” development and as a “little giant” enterprise.

Stepping into the production workshop of Guangxiang Pharmaceutical, one is met with state-of-the-art, modern, and intelligent equipment at every turn. “The promotion and application of advanced manufacturing equipment reflect our vision and confidence in aligning with international industry development. Since the beginning of this year, we have actively implemented digital information management and are committed to building an intelligent API manufacturing plant that meets world-class standards. By adopting new, intelligent polymorph-control technology, we can now precisely regulate product particle size and bulk density, thereby meeting the diverse requirements of high-end customers in Europe and North America. This has significantly improved flow properties for products such as caffeine and metronidazole, earning widespread trust from our clients,” said Cui Yongbin, speaking with evident pride. Through the introduction of cutting-edge, internationally advanced smart manufacturing equipment and core industrial software, followed by deep integration and application, Guangxiang Pharmaceutical has achieved “one-button” control over the entire production process for a range of products—including caffeine, theophylline, aminophylline, metronidazole, and nifedipine—bringing its scale and level of smart manufacturing to a leading position domestically. To date, Guangxiang Pharmaceutical has successively obtained national GMP certification as well as international certifications such as BRC, FSSC 22000, KOSHER, and HALAL, and has established strong cooperative relationships with major global caffeine purchasers.

“Going forward, we will leverage the policy opportunities presented by the national drive to build a unified national market, continue to ramp up investment in innovation, accelerate the implementation of new-product industrialization projects, use high-quality supply to create and lead demand, proactively develop forward-looking and industry-leading market initiatives, and steadily strengthen our appeal in both domestic and international markets,” Cui Yongbin said with full confidence.

Keywords:

Shijiazhuang Sihua Pharmaceutical Group has established an internal system for evaluating and certifying worker technicians, fully implementing a job-based technician program—ensuring that skilled employees are recognized and promoted.

Spring Brings Focus on Major Projects and Bold Development | Gaocheng: Mega Projects Underpin Half of Shijiazhuang’s Pharmaceutical Industry